Real-world adoption of talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer highlights ongoing gaps in homologous recombination (HR) biomarker testing across prostate cancer care.
Andrew Osterland, PharmD
Advertisement
Articles by Andrew Osterland, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Accepts NDA for AD109 for Treatment of Adults With Obstructive Sleep Apnea
2
Men Face Higher Odds of Later-Stage Diagnosis Across 20 Cancer Types
3
Clinical Forum Events Highlight the Evolving Landscape of Obesity Management
4
Workforce Preparation for Fall Immunization Season Starts Now
5